Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Program Description

Despite an overall decline in incidence in gastric cancer in the United States, it remains a significant health burden. Outcomes for patients with advanced gastric cancer are often poor, and most patients require multiple lines of therapy. The development of new targeted therapies and immunotherapies has increased the number of available treatment options, and to ensure appropriate treatment selection oncology pharmacists must consider the efficacy of targeted therapies and immunotherapies based on key biomarkers. However, overlapping biomarkers may present a challenge, as there is often limited clinical evidence to guide treatment decisions in these patients. This webinar will cover the critical role of biomarker testing in gastric cancers as a strategy to guide treatment selection in the frontline and second-line settings. A data review from recent clinical trials informing regulatory decisions will also be discussed. Additionally, the program will emphasize the pharmacist's role in proactive management of treatment-related adverse effects, from medication-specific toxicities to immune-related adverse events, and will offer practical strategies for oncology pharmacists to provide dose modifications and supportive care to enhance patient safety and treatment adherence.
Target audience: Oncology pharmacists

Type of activity: Application

Release date: November 25, 2025

Expiration date: November 25, 2026

Time to complete activity: 1.0 hours

Learner level: Foundational, Intermediate

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify key biomarkers and their relevance in selecting targeted therapies for patients with advanced/metastatic gastric cancer
• Explain the role of current and emerging targeted therapies in the management of advanced/metastatic gastric cancer, incorporating clinical guidelines, recent evidence, and biomarker data
• Employ strategies for managing adverse effects associated with targeted therapies, focusing on improving patient adherence and enhancing overall treatment outcomes
• Explore key considerations for the development and implementation of standardized order sets for novel targeted therapies in gastric cancer, including preparation, dosing, administration, and supportive care measures

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-391-H01-P. The activity is available for CE credit through November 25, 2026

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Matthew Arango, PharmD, BCOP, has the following financial relationships with commercial interests to disclose:
Speakers Bureau and Advisory Board: Astellas Pharma LLC

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms